Global Pathogen Reduction Systems Market to Grow with a CAGR of 8.00% through 2030F
Increasing Awareness and Emphasis on Infection Control and
Rising Incidence of Hospital Associated Infections is expected to drive the
Global Pathogen Reduction Systems Market growth in the forecast period,
2026-2030
According to TechSci Research report, “Global
Pathogen Reduction Systems Market - Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030”, the Global
Pathogen Reduction Systems Market stood at USD 719.06 million in 2024 and is
anticipated to grow with a CAGR of 8.00% in the forecast period, 2026-2030. The
global market for pathogen reduction systems is primarily driven by the
increase in infectious diseases and the growing public awareness of the
importance of safe blood transfusions. Every year, millions of lives are saved
through blood transfusion, which is considered a fundamental pillar of the
modern healthcare system. However, many patients in low- and middle-income
countries still face challenges in accessing timely and secure blood supplies.
Market limitations include concerns about potential influence or damage
to blood cells, as well as the production of harmful chemical agents during
pathogen reduction treatment. The fair remuneration remains a significant
consideration. The evaluation of these innovative technologies will likely be
greatly influenced by ongoing research and development efforts. The expansion
of blood transfusion diagnostics is expected to create more opportunities, as
well as advancements in preventing and eliminating bacterial infiltration in
the blood recipient's body, thus opening doors for the global pathogen
reduction system market.
Despite numerous proactive measures taken to ensure blood safety, such as
strict donor screening, the implementation of new exclusion criteria, and
transfusion hemovigilance, there is still a risk of transfusion-transmitted
infections (TTI). Pathogen reduction systems have been developed to safeguard
the blood supply by inactivating or removing viruses, bacteria, fungi, or
protozoan pathogens. These systems utilize photochemical processes to render
bacteria and viruses inactive, minimizing the risk of infection in blood
products. Various physical, chemical, or photochemical techniques have been
devised to inactivate or reduce pathogens and enhance the safety of the blood
supply. Maintaining platelet activity, crucial for post-transfusion survival
and recovery, is a key aspect of photochemical therapy, which was specifically
developed for platelet therapy.
While the risk factor in pathogen reduction systems is significantly
lower, caution must be exercised when using chemicals in the pathogen reduction
process due to their multiple sites of action. For instance, cross-linking of
lipids in organelles and cell membranes can occur. Protein-protein interactions
between pathogen reduction systems and proteins can lead to malfunctions in
cellular signal transduction, respiratory pathway deficits, or structural
abnormalities. Chemicals attaching to nucleic acids or intercalating nucleic
acid chains can cause errors in transcription, translation, or replication. The
limitations in the market have been significant, with concerns about the
potential influence or damage to blood cells and the production of harmful chemical
agents during pathogen reduction treatment. Fair remuneration is also a
concern. Ongoing research and development will greatly influence the assessment
of these novel technologies. It is predicted that an increase in blood
transfusion diagnostics will create more opportunities. Advancements in
technology to prevent and eliminate bacterial infiltration in blood recipients'
bodies will open up global opportunities in the pathogen reduction system
market.
The risk associated with these systems is minimal, which is why medical
professionals widely adopt them for platelet and plasma reduction from blood
donors. The market is driven by the increasing prevalence of infectious
diseases, rising public awareness of better healthcare facilities, and the
adoption of advanced technologies that result in improved and more effective
pathogen reduction systems.
Pathogen reduction systems are utilized to deactivate viruses and
bacteria that may contaminate blood products. These advanced products utilize
ultraviolet rays in the presence of a photosensitizer to act as a pathogen
inactivator. They are essential in the management of blood transfusion and
pathogen inactivation.
Browse over XX market data Figures spread through XX Pages
and an in-depth TOC on "Global Pathogen Reduction Systems
Market”
The Global Pathogen Reduction Systems
Market is segmented into type, application, product, end user, regional
distribution, and company.
Based on type, Platelet pathogen reduction is the dominant segment in the
global pathogen reduction systems market. This is primarily due to the high
risk of contamination associated with platelet concentrates, which are stored
at room temperature—an environment conducive to bacterial growth. Since
platelets have a short shelf life and are frequently used in critical care,
oncology, and surgical procedures, ensuring their safety is a top priority. Technological advancements and regulatory approvals for platelet pathogen
reduction systems, particularly the INTERCEPT Blood System by Cerus
Corporation, have driven wider adoption in hospitals and blood banks globally.
Platelets are more prone to transfusion-transmitted infections compared to
plasma, making pathogen reduction more essential in this segment. The growing
number of cancer patients and surgeries that require platelet transfusions also
contributes to its dominance. Overall, the urgent need for enhanced safety in
platelet transfusions and the availability of effective technologies make this
segment the market leader.
Based on region, Asia-Pacific is emerging as a rapidly growing region in
the global pathogen reduction systems market, and several factors contribute to
its expanding dominance. The region has witnessed a significant rise in the
number of surgical procedures, trauma cases, and chronic diseases, which in
turn increases the demand for safe blood transfusions. Countries like China,
India, and Japan have large and aging populations, leading to higher healthcare
utilization and a greater need for blood and blood products. The growing
awareness of transfusion-transmitted infections, especially in developing
economies, is driving the adoption of pathogen reduction technologies.
Governments and healthcare institutions are increasingly investing in improving
blood safety standards, backed by global health organizations promoting
infection prevention.
The rapid advancements in healthcare infrastructure, increased healthcare
spending, and favorable regulatory environments are encouraging the
introduction and scaling of advanced medical technologies, including pathogen
reduction systems. Local manufacturing, rising collaborations with global
medical device companies, and supportive public health policies are also
boosting market penetration. The presence of cost-effective manufacturing and a
growing number of clinical research initiatives further enhance the region’s
capacity to implement and scale such systems. Collectively, these factors are
positioning Asia-Pacific as a dominant and high-growth region in the pathogen
reduction systems market.
Major companies operating in Global Pathogen Reduction Systems Market
are:
· Terumo
BCT, Inc.
· Macopharma
SA.
· Cerus
Corporation.
· AngioDynamics,
Inc.
· Octapharma
AG.
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“The increasing prevalence of infectious diseases and growing awareness
regarding the necessity of effective blood transfusions serve as significant
drivers for the global pathogen reduction system market. Blood transfusion is a
fundamental pillar of the modern healthcare system, saving millions of lives
annually. However, many hospital patients in low- and middle-income countries
lack access to timely and safe blood supply. The risk of pathogen and virus
development in blood before transfusion remains significantly high.
Nevertheless, the pathogen reduction treatment presents challenges, including
the risk of affecting or harming blood cells and the generation of toxic
chemical agents. The fair reimbursement issues pose constraints to the global
pathogen reduction system market. Ongoing research and development efforts will
play a crucial role in evaluating these new technologies.,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Global Pathogen Reduction Systems Market By Type (Platelet Pathogen
Reduction, Plasma Pathogen Reduction), By Application (Viruses, Fungi,
Bacteria), By Product (Automated, Semi-Automated), By End User (Hospitals &
Clinics, Ambulatory Care centers, Blood Banks, Others), By Region, By
Competition Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of Global Pathogen
Reduction Systems Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Pathogen
Reduction Systems Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com